The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

Eur Respir J. 2013 Jan;41(1):239-41. doi: 10.1183/09031936.00123612.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Double-Blind Method
  • Female
  • Humans
  • Interleukin-17 / immunology*
  • Leukocyte Disorders / chemically induced*
  • Leukocyte Disorders / drug therapy*
  • Lung Diseases / chemically induced*
  • Lung Diseases / drug therapy*
  • Male
  • Neutrophils / drug effects*
  • Ozone / adverse effects*
  • Time Factors
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • Ozone
  • secukinumab